A Phase 2 interventional study of Bimekizumab and Adalimumab in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 31 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-11.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 56th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2017, is one of 61 in phase 2, and was the 25th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 6 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least
1 year prior to Baseline
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
Drug: Bimekizumab
Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
Drug: Adalimumab
Subjects will receive several placebo applications to keep the blinding.
Other: Placebo
Bimekizumab in different dosages (dose 1 and 2).
Also known as: UCB4940
Adalimumab in different dosages (dose 1, 2 and 3).
Also known as: Humira®
Placebo will be provided matching Bimekizumab.
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
HiSCR was defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count. Results were based on a Bayesian logistic regression model where the number of responders were assumed to follow a binomial distribution. Participants with missing data at Week 12 were considered as nonresponders in the analysis. Posterior mean response rates and 95% credible intervals in each group are presented.
Time frame: Week 12
Bimekizumab Plasma Concentration at Day 1 (Prior to First Dose)
Plasma concentration of Bimekizumab was expressed in nanograms per milliliter (ng/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (75 ng/mL) in calculations of Means and Coefficient of Variations (CVs).
Time frame: Day 1 (Prior to first dose)
Bimekizumab Plasma Concentration at Week 2
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
Time frame: Week 2
Bimekizumab Plasma Concentration at Week 4
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
Time frame: Week 4
Bimekizumab Plasma Concentration at Week 8
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
Time frame: Week 8
Bimekizumab Plasma Concentration at Week 12
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
Time frame: Week 12
Bimekizumab Plasma Concentration at Week 30
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
Time frame: Week 30
Percentage of Participants With at Least One Adverse Event During the Study
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From Screening to Safety Follow-Up (Week 30)
Percentage of Participants With at Least One Adverse Event Categorized by Maximum Severity During the Study
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. To record the intensity of an AE Investigator used the following criteria: Mild: the study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with the usual activities of the study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.
Time frame: From Screening to Safety Follow-Up (Week 30)
Percentage of Participants With at Least One Serious Adverse Event During the Study
A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalisation, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above.
Time frame: From Screening to Safety Follow-Up (Week 30)
Percentage of Participants With at Least One Serious Adverse Event Categorized by Severity During the Study
A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above. To record the intensity of an AE Investigator used the following criteria: Mild: study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with usual activities of study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.
Time frame: From Screening to Safety Follow-Up (Week 30)
Percentage of Participants That Withdrew Due to Adverse Events During the Study
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From Screening to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)
Blood pressure was measured in millimeters of mercury (mmHg).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)
Pulse rate was measured in beats per minute (beats/min).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Body Weight
Body weight was measured in kilograms (kg).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate)
Electrocardiogram (ECG) Mean Heart Rate was measured in beats/min.
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in ECG Parameters (PR Interval, QRS Duration, QT Interval, QTcF Interval)
PR Interval, QRS duration, QT interval and QT corrected for heart rate using Fridericia's correction (QTcF) Interval were measured in milliseconds (msec).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)
Erythrocytes was measured in number of red blood cells per liter (10\^12/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)
Hematocrit was measured in volume percentage (%) of red blood cells in blood.
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hemoglobin, Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration)
Hemoglobin, erythrocytes mean corpuscular hemoglobin (HGB) concentration were measured in grams per liter (g/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))
Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)
Erythrocytes mean corpuscular volume was measured in femtoliters (fL).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)
Platelets was measured in number of platelets per liter (10\^9/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils)
Leukocytes, basophils, eosinophils, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\^9/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes)
Basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes were measured in percentages (%).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Bicarbonate, Chloride, Potassium, Sodium, Calcium, Magnesium, Urea Nitrogen, Cholesterol, Glucose)
Bicarbonate, chloride, potassium, sodium, calcium, magnesium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin, Urate)
Creatinine, bilirubin, and urate were measured in micromols per liter (μmol/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity)
C reactive protein high sensitivity was measured in milligrams per liter (mg/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)
Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH)
Urine pH was measured on a pH scale.
Time frame: From Baseline to Safety Follow-Up (Week 30)
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin)
Urine albumin was measured in milligrams per liter (mg/L).
Time frame: From Baseline to Safety Follow-Up (Week 30)
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Glucose)
Time frame: From Baseline to Safety Follow-Up (Week 30)
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Leukocyte Esterase)
Time frame: From Baseline to Safety Follow-Up (Week 30)
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Bacteria)
Time frame: From Baseline to Safety Follow-Up (Week 30)
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Erythrocytes)
Time frame: From Baseline to Safety Follow-Up (Week 30)
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Physical Examination
Time frame: From Baseline to Safety Follow-Up (Week 30)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 1
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Day 1
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 2
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Week 2
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 4
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Week 4
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 8
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Week 8
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 12
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Week 12
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 30
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
Time frame: Week 30
The study started to enroll patients in September 2017 and concluded in February 2019.
| Milestone | Placebo | Adalimumab | Bimekizumab |
|---|---|---|---|
| Started | 22 | 22 | 46 |
| Completed week 12 | 19 | 18 | 42 |
| Completed | 18 | 17 | 38 |
| Not completed | 4 | 5 | 8 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 |
| Withdrew: Sponsor request | 0 | 2 | 0 |
HiSCR was defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count. Results were based on a Bayesian logistic regression model where the number of responders were assumed to follow a binomial distribution. Participants with missing data at Week 12 were considered as nonresponders in the analysis. Posterior mean response rates and 95% credible intervals in each group are presented.
| Percentage of responders | Placebo (PPS) | Adalimumab (PPS) | Bimekizumab (PPS) |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 26.1 (13.8 to 40.5) | 59.5 (44.2 to 73.9) | 57.3 (42.4 to 71.4) |
Plasma concentration of Bimekizumab was expressed in nanograms per milliliter (ng/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (75 ng/mL) in calculations of Means and Coefficient of Variations (CVs).
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Day 1 (Prior to First Dose) | NA ± NA |
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Week 2 | 24086.4 ± 56.4 |
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Week 4 | 26572.6 ± 57.6 |
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Week 8 | 30222.6 ± 54.5 |
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Week 12 | 25319.0 ± 116.8 |
Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.
| ng/mL | Bimekizumab (PK-PPS) |
|---|---|
| Bimekizumab Plasma Concentration at Week 30 | NA ± NA |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| percentage of participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event During the Study | 61.9 | 71.4 | 71.7 |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. To record the intensity of an AE Investigator used the following criteria: Mild: the study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with the usual activities of the study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.
| percentage of participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Mild | 47.6 | 66.7 | 63.0 |
| Moderate | 33.3 | 42.9 | 39.1 |
| Severe | 4.8 | 9.5 | 6.5 |
A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalisation, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above.
| percentage of participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Percentage of Participants With at Least One Serious Adverse Event During the Study | 9.5 | 4.8 | 4.3 |
A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above. To record the intensity of an AE Investigator used the following criteria: Mild: study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with usual activities of study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.
| percentage of participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Mild | 0 | 4.8 | 0 |
| Moderate | 4.8 | 0 | 0 |
| Severe | 4.8 | 4.8 | 4.3 |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| percentage of participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Percentage of Participants That Withdrew Due to Adverse Events During the Study | 0 | 0 | 2.2 |
Blood pressure was measured in millimeters of mercury (mmHg).
| mmHg | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Systolic Blood Pressure | -2.9 ± 14.8 | 4.5 ± 14.5 | -0.4 ± 13.8 |
| Diastolic Blood Pressure | -1.8 ± 8.4 | -0.6 ± 9.1 | -2.2 ± 11.2 |
Pulse rate was measured in beats per minute (beats/min).
| beats/min | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate) | -1.4 ± 10.2 | -1.8 ± 10.8 | -1.6 ± 10.8 |
Body weight was measured in kilograms (kg).
| kg | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Body Weight | 0.90 ± 7.39 | 1.82 ± 3.94 | 0.42 ± 6.89 |
Electrocardiogram (ECG) Mean Heart Rate was measured in beats/min.
| beats/min | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate) | -2.1 ± 12.4 | -2.1 ± 11.1 | 1.5 ± 10.1 |
PR Interval, QRS duration, QT interval and QT corrected for heart rate using Fridericia's correction (QTcF) Interval were measured in milliseconds (msec).
| msec | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| PR Interval | 0.8 ± 18.8 | 2.4 ± 10.5 | 3.6 ± 18.7 |
| QRS duration | -0.3 ± 7.1 | 0.2 ± 5.2 | 0.6 ± 7.4 |
| QT interval | 4.8 ± 20.2 | 4.2 ± 26.7 | 1.8 ± 27.7 |
| QTcF Interval | -11.7 ± 49.9 | -0.3 ± 14.4 | 2.4 ± 12.7 |
Erythrocytes was measured in number of red blood cells per liter (10\^12/L).
| 10^12 red blood cells per liter | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes) | 0.144 ± 0.349 | -0.151 ± 0.416 | -0.013 ± 0.274 |
Hematocrit was measured in volume percentage (%) of red blood cells in blood.
| volume % of red blood cells | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit) | 2.01 ± 2.83 | -0.81 ± 4.30 | 0.39 ± 2.69 |
Hemoglobin, erythrocytes mean corpuscular hemoglobin (HGB) concentration were measured in grams per liter (g/L).
| g/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Hemoglobin | 5.3 ± 11.6 | -3.7 ± 11.6 | 1.1 ± 7.6 |
| Erythrocytes mean corpuscular HGB | -1.4 ± 16.2 | -2.6 ± 13.4 | -0.2 ± 13.2 |
Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
| picograms (pg) | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) | 0.29 ± 0.76 | 0.21 ± 0.78 | 0.30 ± 0.99 |
Erythrocytes mean corpuscular volume was measured in femtoliters (fL).
| femtoliters (fL) | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume) | 1.49 ± 2.95 | 1.36 ± 3.21 | 1.04 ± 4.03 |
Platelets was measured in number of platelets per liter (10\^9/L).
| 10^9 platelets per liter | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets) | -17.4 ± 38.7 | 2.3 ± 61.6 | -19.2 ± 51.4 |
Leukocytes, basophils, eosinophils, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\^9/L).
| 10^9 white blood cells per liter | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Leukocytes | -0.281 ± 2.621 | -0.114 ± 2.997 | -0.122 ± 2.308 |
| Basophils | 0.009 ± 0.026 | 0.033 ± 0.077 | 0.015 ± 0.048 |
| Eosinophils | 0.007 ± 0.077 | -0.012 ± 0.100 | 0.002 ± 0.056 |
| Lymphocytes | 0.029 ± 0.812 | 0.241 ± 0.682 | 0.038 ± 0.570 |
| Monocytes | 0.072 ± 0.420 | -0.032 ± 0.322 | 0.060 ± 0.192 |
| Neutrophils | -0.396 ± 2.076 | -0.341 ± 2.460 | -0.240 ± 2.234 |
Basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes were measured in percentages (%).
| % of white blood cells per leukocytes | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Basophils/leukocytes | 0.13 ± 0.23 | 0.42 ± 0.93 | 0.13 ± 0.65 |
| Eosinophils/leukocytes | -0.12 ± 1.92 | -0.03 ± 1.09 | 0.12 ± 1.12 |
| Lymphocytes/leukocytes | 1.43 ± 5.47 | 2.04 ± 6.73 | 2.04 ± 8.07 |
| Monocytes/leukocytes | 0.49 ± 4.35 | -0.20 ± 2.79 | 1.00 ± 2.17 |
| Neutrophils/leukocytes | -1.93 ± 6.84 | -2.24 ± 7.50 | -3.29 ± 9.55 |
Bicarbonate, chloride, potassium, sodium, calcium, magnesium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).
| mmol/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Bicarbonate | -0.1 ± 2.1 | 0.7 ± 2.8 | 0.6 ± 2.3 |
| Chloride | 0.9 ± 1.5 | 1.3 ± 2.4 | 0.1 ± 2.2 |
| Potassium | -0.13 ± 0.79 | -0.09 ± 0.37 | 0.03 ± 0.41 |
| Sodium | 0.4 ± 1.5 | 0.4 ± 1.6 | 0.1 ± 2.2 |
| Calcium | 0.027 ± 0.065 | 0.008 ± 0.144 | 0.067 ± 0.095 |
| Magnesium | -0.029 ± 0.087 | -0.027 ± 0.052 | -0.009 ± 0.081 |
| Urea nitrogen | 0.00 ± 1.46 | -0.43 ± 1.37 | 0.29 ± 1.79 |
| Cholesterol | -0.311 ± 0.667 | -0.177 ± 0.634 | 0.157 ± 0.585 |
| Glucose | 1.049 ± 1.835 | 0.436 ± 2.990 | 0.439 ± 2.212 |
Creatinine, bilirubin, and urate were measured in micromols per liter (μmol/L).
| μmol/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Creatinine | -1.73 ± 9.92 | -1.72 ± 9.04 | 3.84 ± 9.22 |
| Bilirubin | 0.17 ± 3.48 | -1.38 ± 3.04 | 0.18 ± 4.35 |
| Urate | 8.7 ± 52.2 | -8.9 ± 50.5 | 1.5 ± 43.1 |
C reactive protein high sensitivity was measured in milligrams per liter (mg/L).
| mg/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity) | -2.801 ± 16.851 | -4.865 ± 21.863 | -2.810 ± 10.853 |
Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).
| U/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Alanine aminotransferase | -3.3 ± 8.3 | -3.6 ± 9.8 | 3.6 ± 23.8 |
| Alkaline phosphatase | -2.0 ± 12.2 | -2.4 ± 13.5 | -3.4 ± 11.6 |
| Aspartate aminotransferase | -0.6 ± 3.6 | -1.0 ± 5.8 | 2.0 ± 13.3 |
| Gamma glutamyl transferase | -2.0 ± 9.5 | 1.8 ± 14.2 | 2.3 ± 10.1 |
| Lactate dehydrogenase | -17.0 ± 29.9 | -16.3 ± 35.6 | -12.8 ± 61.8 |
Urine pH was measured on a pH scale.
| pH | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH) | -0.43 ± 0.98 | -0.25 ± 0.55 | -0.03 ± 0.69 |
Urine albumin was measured in milligrams per liter (mg/L).
| mg/L | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin) | 50.80 ± 211.30 | -28.25 ± 121.29 | 0.49 ± 19.92 |
| Participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Baseline Low - Week 30 Low | 0 | 0 | 0 |
| Baseline Low - Week 30 Normal | 0 | 0 | 0 |
| Baseline Low - Week 30 High | 0 | 0 | 0 |
| Baseline Normal - Week 30 Low | 0 | 0 | 0 |
| Baseline Normal - Week 30 Normal | 12 | 14 | 28 |
| Baseline Normal - Week 30 High | 1 | 1 | 0 |
| Baseline High - Week 30 Low | 0 | 0 | 0 |
| Baseline High - Week 30 Normal | 0 | 1 | 1 |
| Baseline High - Week 30 High | 1 | 0 | 2 |
| Participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Baseline Low - Week 30 Low | 0 | 0 | 0 |
| Baseline Low - Week 30 Normal | 0 | 0 | 0 |
| Baseline Low - Week 30 High | 0 | 0 | 0 |
| Baseline Normal - Week 30 Low | 0 | 0 | 0 |
| Baseline Normal - Week 30 Normal | 8 | 9 | 19 |
| Baseline Normal - Week 30 High | 2 | 0 | 6 |
| Baseline High - Week 30 Low | 0 | 0 | 0 |
| Baseline High - Week 30 Normal | 2 | 3 | 6 |
| Baseline High - Week 30 High | 2 | 4 | 0 |
| Participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Baseline Low - Week 30 Low | 0 | 0 | 0 |
| Baseline Low - Week 30 Normal | 0 | 0 | 0 |
| Baseline Low - Week 30 High | 0 | 0 | 0 |
| Baseline Normal - Week 30 Low | 0 | 0 | 0 |
| Baseline Normal - Week 30 Normal | 0 | 0 | 0 |
| Baseline Normal - Week 30 High | 0 | 0 | 0 |
| Baseline High - Week 30 Low | 0 | 0 | 0 |
| Baseline High - Week 30 Normal | 0 | 0 | 0 |
| Baseline High - Week 30 High | 3 | 6 | 2 |
| Participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Baseline Low - Week 30 Low | 0 | 0 | 0 |
| Baseline Low - Week 30 Normal | 0 | 0 | 0 |
| Baseline Low - Week 30 High | 0 | 0 | 0 |
| Baseline Normal - Week 30 Low | 0 | 0 | 0 |
| Baseline Normal - Week 30 Normal | 1 | 0 | 1 |
| Baseline Normal - Week 30 High | 0 | 0 | 0 |
| Baseline High - Week 30 Low | 0 | 0 | 0 |
| Baseline High - Week 30 Normal | 0 | 0 | 0 |
| Baseline High - Week 30 High | 2 | 1 | 0 |
| Participants | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Baseline Normal - Week 30 Normal | 14 | 15 | 28 |
| Baseline Normal - Week 30 Abnormal | 1 | 2 | 5 |
| Baseline Abnormal - Week 30 Normal | 1 | 1 | 1 |
| Baseline Abnormal - Week 30 Abnormal | 2 | 1 | 4 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 1 | 4.3 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 2 | 4.4 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 4 | 4.3 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 8 | 0 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 12 | 9.5 |
The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.
| percentage of participants | Bimekizumab (PK-PPS) |
|---|---|
| Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 30 | 13.9 |
Collected over Treatment-emergent adverse events (TEAEs) were collected from Baseline (Day 1) until the Safety Follow-Up Visit (Week 30). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (SS) | 0/21 (0%) | 2/21 (9.5%) | 5/21 (23.8%) |
| Adalimumab (SS) | 0/21 (0%) | 1/21 (4.8%) | 12/21 (57.1%) |
| Bimekizumab (SS) | 0/46 (0%) | 2/46 (4.3%) | 21/46 (45.7%) |
| Event | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 1/21 | 0/21 | 0/46 |
| HeadacheNervous system disorders | 1/21 | 0/21 | 0/46 |
| DizzinessNervous system disorders | 1/21 | 0/21 | 0/46 |
| HypoaesthesiaNervous system disorders | 1/21 | 0/21 | 0/46 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/21 | 1/21 | 0/46 |
| AnaemiaBlood and lymphatic system disorders | 0/21 | 0/21 | 1/46 |
| EmpyemaInfections and infestations | 0/21 | 0/21 | 1/46 |
| Event | Placebo (SS) | Adalimumab (SS) | Bimekizumab (SS) |
|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 3/21 | 6/21 | 8/46 |
| InfluenzaInfections and infestations | 0/21 | 3/21 | 0/46 |
| HeadacheNervous system disorders | 3/21 | 0/21 | 3/46 |
| FatigueGeneral disorders | 0/21 | 2/21 | 4/46 |
| PyrexiaGeneral disorders | 0/21 | 2/21 | 1/46 |
| Injection site pruritusGeneral disorders | 0/21 | 2/21 | 2/46 |
| Upper respiratory tract infectionInfections and infestations | 0/21 | 2/21 | 2/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/21 | 2/21 | 1/46 |
| DiarrhoeaGastrointestinal disorders | 0/21 | 1/21 | 3/46 |
| NauseaGastrointestinal disorders | 0/21 | 1/21 | 3/46 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants randomized into the study.
| Age, Categorical(Participants) | Placebo | Adalimumab | Bimekizumab | Total Title |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 2 | 2 |
| Between 18 and 65 years | 21 | 22 | 44 | 87 |
| >=65 years | 1 | 0 | 0 | 1 |
| Age, Continuous(years) | Placebo | Adalimumab | Bimekizumab | Total Title |
|---|---|---|---|---|
| Mean | 40.7 ± 12.5 | 31.0 ± 9.2 | 37.4 ± 11.9 | 36.6 ± 11.9 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab | Bimekizumab | Total Title |
|---|---|---|---|---|
| Female | 15 | 18 | 30 | 63 |
| Male | 7 | 4 | 16 | 27 |
| Race/Ethnicity, Customized(Participants) | Placebo | Adalimumab | Bimekizumab | Total Title |
|---|---|---|---|---|
| American Indian or Alaskan Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 3 | 0 | 4 |
| Black or African American | 6 | 5 | 10 | 21 |
| White | 12 | 14 | 35 | 61 |
| Other or Mixed | 2 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Nov 2018, 14 months.
Results were first posted in Feb 2022, 3 years 2 months after primary completion. A results delay was requested in Nov 2019.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 14 months is close to that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab